Astra Zeneca AG

Our core business is the development and marketing of medicines. Currently, over 230,000
people treated with a drug from AstraZeneca.
Between 2025 and 2027, the company expects more than 35 new therapies to be approved. We are constantly striving to do our part to make the Swiss healthcare system more sustainable, robust and fit for the future. With this goal in mind, we work together with various stakeholder groups - far beyond our core business.